![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 3, 2024
GI Cancer Committee displays strong representation at ASCO; real-world data study nears activation; ECOG-ACRIN commends NCI's appointment of senior advisor for clinical research
July 3, 2024
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
July 3, 2024
The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread
July 3, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 11, 2024
A Spring Group Meeting recap; a milestone for TMIST; a new myeloMATCH treatment trial
May 1, 2024
A new trial in sarcoma; MSI testing for gastroesophageal cancer; Spring Group Meeting and ASCO highlights
April 9, 2024
A new trial in glioblastoma; leadership transitions; upcoming Group Meeting highlights
March 7, 2024
Big data projects near activation; APP Working Group builds momentum; ECOG-ACRIN welcomes Winn CILA scholar
February 9, 2024
The co-chairs commemorate the late Dr. Edith Mitchell, welcome the new NCI Director, and reflect on the DREAMseq melanoma trial results
February 9, 2024
In January, the medical community lost an acclaimed oncology physician, researcher, teacher, and health equity pioneer
February 9, 2024
Amidst a persistent drug shortage, the BRIDGE trial seeks another possible first-line treatment option for patients
February 9, 2024
A member of ECOG-ACRIN since 2014